-Date: November 2, 2023 - Parties: Janssen Inc. and Janssen Pharmaceutica N.V. (Plaintiffs) vs. Pharmascience Inc. (Defendant) - Financial Award/Costs: The court had awarded Janssen 25% of reasonable legal fees and 100% of reasonable disbursements, exclusive of certain motions, with specified limitations. The total claimed costs had been initially $774,178.79. - Assessment Process: Janssen had initiated a request for cost assessment in November 2022, followed by the filing of additional documents by both parties. - Janssen's Claim: Janssen had argued that their costs were reasonable, citing intellectual property case norms and relevant case law to support their claim. - Pharmascience's Counter: Pharmascience had contended that Janssen's claimed costs lacked evidence of reasonableness and had sought reductions in various cost categories, totaling $334,742.00. - Janssen's Response: Janssen had defended the reasonableness of most costs but had conceded deductions in certain categories, reducing their claimed costs to $715,634.72. - Assessment Criteria: The assessment officer had reviewed claims considering the court's instructions, existing cost case law, and the burden of proof on Janssen to demonstrate the reasonableness of costs. - Conclusion: After assessment, the court had allowed Janssen's costs in the amount of $702,927.99, with 2.5% post-judgment interest, payable by Pharmascience Inc.